Bristol-Myers Squibb has bought itself access to an undisclosed immunoscience programme owned by Danish group Novo Nordisk.
Details are scant, but it was revealed that the deal sees B-MS acquire an exclusive global license to a discovery biologics research programme focused on modulating the innate immune system – the body’s first line of defence – to fight autoimmune diseases.
Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases, B-MS noted, explaining its interest in the deal.
Novo announced last Septmber that it is pulling out of inflammatory disorder R&D to increase its diabetes and obesity efforts.
